Top Health Tech Companies in Belfast (31)
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Strong Revenue Growth: Evidence points to ARR reaching about $210M with continued year-over-year increases, and company statements indicate surpassing $200M in annualized revenue. Feedback suggests upselling and higher average revenue per customer support expansion from existing accounts.
Market Expansion: Adoption reportedly grew from ~410 customers in 2020 to 1,200+ by 2024, with 240 new customers added in 2024 and penetration into top-50 global biopharma firms. Feedback suggests partnerships and geographic breadth bolster reach across biotech and pharma.
Innovation-Driven Growth: Product launches in AI, automation, and broader R&D workflows, plus acquisitions and collaborations (e.g., Lilly TuneLab, NVIDIA) indicate active investment in next-generation capabilities. Feedback suggests these moves expand use cases and deepen platform integration in labs.
ResMed provides medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
ResMed's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.
Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.
Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.
Organon is a global healthcare company with a portfolio of therapies and products in women’s health, biosimilars, and established medicines across a wide array of conditions and diseases. Our mission is to deliver impactful medicines and solutions for a healthier every day. This site is intended for residents of the United States and its territories. You are reminded to protect yourself...
Organon's Top Stability & Growth Strengths
Strong Market Position & Advantage: Organon is repeatedly characterized as a leader in women’s health, with Nexplanon anchoring a dominant position in contraceptive implants and an extended label that reinforces its edge. A broad footprint across 140+ markets and focus on conditions affecting women underpin this positioning.
Healthy Cash Flow: Established brands are described as providing stable cash flows that fund R&D and growth initiatives in women’s health and biosimilars. Despite mixed topline trends, management highlights ongoing cash generation supporting deleveraging and reinvestment.
Strategic Partnerships: Partnerships such as Samsung Bioepis in biosimilars and commercial collaborations with large biopharma companies expand the portfolio and market access. A pipeline supported by multiple alliances is cited as a core pillar of its strategy.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 20,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology,...
Henry Schein's Top Stability & Growth Strengths
Strong Market Position & Advantage: Regulators, company filings, and independent coverage characterize Henry Schein as a top full‑service dental distributor with global scale and Fortune 500 standing. Its role in an FTC‑recognized oligopoly and breadth across distribution and software reinforce durable competitive advantages.
Resilient & Sustainable Growth: Recent results indicate steady year‑over‑year increases in sales and EPS, and management has reaffirmed guidance for modest top‑line and EBITDA growth. Share repurchases and a multi‑year operating‑income improvement program support a measured compounding profile.
Future-Ready Strategy: The company is investing in higher‑growth technology and value‑added services and pursuing AI‑enabled initiatives alongside a defined multi‑year operating plan. Portfolio moves in software, digital solutions, and specialty offerings are positioned to create switching costs and embed workflows in practices.
Data Mastery is a data consultancy based in the Belfast and Dublin, helping organisations transform how they collect, model, and leverage data. We specialise in designing and delivering modern analytics solutions built on Azure, Microsoft Fabric and Power BI, enabling business users to make confident, data-informed decisions. Our approach is deeply consultative: we embed ourselves within client teams to understand business...
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and...
Sanofi's Top Stability & Growth Strengths
Strong Revenue Growth: Sales growth is described as strong, with 2025 net sales up at constant exchange rates and Q4 showing further acceleration, indicating momentum into 2026.
Profitability: Earnings expansion is described as outpacing sales growth in 2025, and 2026 guidance indicates continued profitable expansion with EPS growing slightly faster than sales.
Product Line Growth: Newer launches are scaling rapidly, with notable growth in recent pharma launches and contributions from products beyond the flagship franchise, helping broaden growth drivers.
Locate a Locum uses innovative marketplace technology through a website and app to mobilise the world's healthcare workforce. Locate a Locum has helped drive a digital revolution in healthcare. As well as working in a day-to-day capacity to place healthcare workers, Locate a Locum also has a business solution that provides healthcare workforce management, including Rota, Leave, Time & Attendance, Payments,...
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock. We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of...
IDEXX's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market leadership in companion-animal diagnostics, reference labs, and veterinary software is repeatedly emphasized, underpinned by an integrated, closed-loop ecosystem that raises switching costs. Feedback suggests this position is reinforced by a broad global footprint and a large installed base of analyzers and labs.
Strong Revenue Growth: Revenue and earnings are described as steadily increasing, with recent quarters surpassing expectations and prompting raised full-year guidance. Company updates point to continued momentum across core segments.
Customer Loyalty & Retention: Bundled point-of-care equipment, consumables, reference-lab services, and practice software create sticky, recurring relationships and high utilization. The ‘razor/razorblade’ model supports repeat purchasing and long-term engagement with clinics.
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Viatris's Top Stability & Growth Strengths
Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.
Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.
Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.
We constantly hear how healthcare systems are under pressure or broken and that healthcare is mired in siloed systems. But what if the visible cracks in healthcare were actually symptoms of not embracing the digital transformation other industries have used to flourish? Not giving our frontline heroes the tools required to do their job? What if we reimagined how care...
Affidea is a pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider, operating in Greece since 2005 to offer high-quality, integrated primary health services.
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter...
Beckman Coulter Diagnostics's Top Stability & Growth Strengths
Strong Market Position & Advantage: Beckman Coulter Diagnostics is widely recognized as a leader in core‑lab IVD with broad adoption of its chemistry, immunoassay, and automation platforms, supported by Danaher’s top‑tier diagnostics portfolio. Multiple analyses place Danaher (including Beckman) among the leading global diagnostics groups, underscoring substantial installed base and reach.
Innovation-Driven Growth: Recent FDA clearances (e.g., DxC 500i, NT‑proBNP on DxI 9000), Breakthrough Device designation for an Alzheimer’s blood test, and expansion of the DxI 9000 assay menu (including neurodegenerative markers) demonstrate an active pipeline. Research‑use‑only biomarker assays and ongoing menu additions further support platform adoption and reagent pull‑through.
Resilient & Sustainable Growth: Management highlighted mid‑single‑digit growth through 2025, with multiple consecutive quarters of mid‑single‑digit or better growth outside China and expectations for gradual end‑market improvement into 2026. The IVD and clinical chemistry analyzer markets are expanding, providing supportive demand tailwinds.
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
At Elanco, we work to improve the health of animals through innovative products and services for pets and farm animals around the world. As a global animal health company, we provide solutions that empower our customers to advance a vision of Food and Companionship Enriching Life. Since 1954, Elanco has committed to empowering veterinarians, farmers, and all those who care...
Elanco's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is growing year over year with acceleration in the latest quarter, and guidance indicates continued organic expansion into 2026.
Innovation-Driven Growth: Innovation revenue surpassed targets and management raised the next-year goal, supported by new launches such as Befrena, Credelio Quattro, Zenrelia, AdTab, and Experior.
Future-Ready Strategy: A multi‑year plan calls for ongoing organic growth and improving earnings metrics, underpinned by a late‑stage pipeline expected to deliver multiple potential blockbusters through 2026–2031.
Welcome! We are Northern Ireland’s Premier Private Healthcare Group. Our mission is to become a world-class provider of healthcare solutions by putting our patients to the forefront of everything we do. Our aim is to make the Kingsbridge Healthcare Group the preferred choice for both patients and healthcare professionals. Because Life Matters. Companies within the Kingsbridge Healthcare Group include: Kingsbridge...
We are a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, extraordinary talent and innovation, we ‘create better together’ by partnering with healthcare professionals. Our extensive range of products, services and integrated technologies fuel active lifestyles.
Enovis's Top Stability & Growth Strengths
Strong Revenue Growth: Full-year 2025 revenue reached about $2.2–$2.248B, described as up year over year with organic growth also cited, and 2026 guidance indicates continued expansion. Multi-year net sales progression from 2023 to 2025 is presented as consistently upward, with Reconstructive repeatedly cited as the primary growth engine.
Innovation-Driven Growth: The company is characterized as innovation-driven, highlighting investments such as the ARVIS Gen 2 augmented reality system and a steady cadence of new product launches across reconstructive and prevention/recovery offerings. Digital enablement and technology differentiation are framed as key enablers of share gains, especially in faster-growing niches like extremities/shoulder.
Strong Market Position & Advantage: Category leadership is asserted in bracing and rehab through legacy DJO brands (DonJoy, Aircast, Chattanooga), and the LimaCorporate acquisition is described as elevating the company into a top-tier position in extremities. The portfolio is positioned as strong in select segments even if not dominant across the entire orthopedic implant market.
Connected Health is a Northern Ireland homecare provider delivering high-quality private healthcare services in people’s homes and communities. Its services support independent living through personalised personal care, lifestyle assistance, companionship, dementia care, and hospital-to-home re-enablement. The organisation also uses technology-enabled care, training, and coordinated support to improve wellbeing, prevent ill health, reduce avoidable hospitalisation, and support clients and families.
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with...
Stryker's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double-digit annual sales expansion through 2025, with management guiding to continued organic growth into 2026.
Strong Market Position & Advantage: Evidence highlights leadership in orthopedic robotics and top-tier standings among global medtech peers, with notable share in joint replacement and integrated OR technologies.
Diversified Revenue Streams: Multiple segments and recent vascular-focused acquisitions broaden growth drivers and reduce reliance on any single category.
Blue Zinc is a technology company in the health industry, specialising in improving, connecting and automating the musculoskeletal and talking therapies arenas. We produce solutions for all parts of the market, from funders to practitioners.
System C Healthcare is a British health and social care technology company founded in 1983. It develops and deploys IT products and services for the NHS, social service authorities and social care providers. Through its Liquidlogic subsidiary, the company supplies social care and education management solutions that facilitate collaboration across health and care services. Its mission is to deliver technology...
